Head-to-head · WeighScore
Medro vs Ravia Health
The verdict
Medro takes it — 63.6/100 to 59.2/100.
Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Medro | Ravia Health |
|---|---|---|
| WeighScore | 63.6/100 | 59.2/100 |
| Grade | C | C |
| Scorecard rank | #255 | #347 |
| Semaglutide | $199/mo (compounded) | Not disclosed |
| Tirzepatide | $299/mo (compounded) | Not disclosed |
| Coverage | All 50 states | 1 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #255 · C
Strengths
- Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
- LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
- No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
- Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).
Where it loses points
- Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
- Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
- Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
- Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Graded #347 · C
Strengths
- Integrative psychiatry model combines GLP-1 weight-loss with mental health and metabolic care under one board-certified NP provider
- Founded by Dr. Raashida Portier (DNP, PMHNP-BC, FNP-BC); named clinician with dual board certifications in psychiatry and family medicine
- Membership-supported ongoing care from $49/month provides medication management structure with consistent follow-up
- Labs and metabolic workup available as part of integrative psychiatry model; lab testing noted in weight-loss program
- Weight-loss page claims nationwide availability via Lyv Health partnership for eligible patients
Where it loses points
- GLP-1 medication pricing fully gated — not disclosed until consultation; compounded vs. brand status unclear on public pages
- Primarily a psychiatric practice — weight loss is a secondary service, not the core offering or brand identity
- Core services explicitly Florida-only; nationwide weight-loss claim relies on Lyv Health partnership with unverified state coverage
- No LegitScript certification or third-party accreditation found on public pages
- Small single-provider practice with no published outcomes data or external reviews available
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.